Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 350

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 8
Chunk 350
---
$(34,550)$(20,399)$(14,151)

21

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Six Months Ended June 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$16,931 $7,773 $9,158 Complementary modulator programs2,281 4,135 (1,854)Unallocated research and development expenses:Personnel-related (including stock-based compensation)6,764 4,182 2,582 Other R&D related costs1,917 1,105 812 Facility, lab and depreciation1,158 1,258 (100)Total research and development expenses$29,051 $18,453 $10,598 

(1)NBD1 and combination development program costs include NBD1 stabilizer activities and development of our proprietary combination therapy. Complementary modulator program costs include manufacturing expenses for the complementary modulators.

Research and development expenses increased by $10.6 million to $29.1 million for the six months ended June 30, 2025, from $18.5 million for the six months ended June 30, 2024. The increase in research and development expenses was primarily due to:

•direct research and development expenses increased by $7.3 million primarily due to an increase in clinical programs and combination development activities; and

•unallocated research and development expenses increased by $3.3 million primarily due to a $2.6 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the size of our workforce to support our clinical pipeline. 

General and Administrative Expenses

The following table summarizes our general and administrative expenses (in thousands):

Six Months Ended June 30,Change20252024Personnel-related (including stock-based compensation)$7,697 $3,411 $4,286 Professional services & fees3,908 1,819 2,089 Facility and depreciation909 756 153 Total general and administrative expenses$12,514 $5,986 $6,528 

General and administrative expenses increased by $6.5 million to $12.5 million for the six months ended June 30, 2025, from $6.0 million for the six months ended June 30, 2024. The increase in general and administrative expenses was